text here that is the new abstract information for your application. This section must be no Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Project Summary (Change of Scope) Modified Project Summary (Change of Scope) U01 A1082015-O1 "Broad Spectrum Therapeutics Targeting UO1 AI082015-01 "Broad Spectrum Therapeutics Targeting Resolvase Enzymes" For applications in biodefense, it is desirable for small molecule inhibitors to biodefense, target multiple category A-C agents because it is difficult and expensive to develop even one small molecule inhibitor. We propose to develop inhibitors of molecule inhibitor. We propose Holliday junction resolvase enzymes, which are found in several category A-C Initial studies focused on resolvase enzymes agents. Initial studies focused on resolvase enzymes found in poxviruses. These enzymes catalyze a required replication step in which concatemers of the viral genomic DNA are cleaved into unit length genomes for packaging. The cleaved into unit length genomes for packaging. enzyme is also important in pathogenic fungi such as Coccidioldes, the causative Coccidioides, Fever, where agent of Valley Fever, where it is involved in mitochondrial DNA replication. In involved in mitochondrial DNA replication. previous work we developed a high throughput assay and screened >133,000 Our best compound so far has an IC50 small molecules for inhibitory activity. Our best compound so far has an 1C50 against purified resolvase of -100 nM, 1C50 against virus of 3 uM. We have -100 nM, IC50 against virus of 3 uM. revised our Aims in accordance with the reviewers comments, and to maximize our progress over the projected two years (instead of five years) of funding. We projected two years (instead of five years) of funding. will emphasize new compound identification, iterative compound synthesis, and increasingly stringent assays to develop inhibitors of poxvirus resolvases that are active in animal models. Inhibitors active against poxviruses in vivo will also be models. Inhibitors active against poxviruses tested in pathogenic fungi in an effort to develop "dual use" pharmacotherapy. pathogelllic Funding of the project will generate jobs for more than five people (5.45 FTEs summed over all the participating groups). and two pieces of equipment will be purchased (a fluorescence plate reader and a -80�C freezer) from American sources. advancing the goals of the ARRA. sources, thereby advancing the goals of the ARRA. -(} -�O D)� ... 10 11:20AM (GMT-04:00) 11 :20AM (GMT-014:OO) 06/19/2009 too r=` Ofd :mN 0)_ d-0 =ii =d0 a-Ec w-w goo 06/19/2009 10:31 FAX 06/19/2009 215 9557 215 898 9557 UPENN MICROBIOLOGY t012/025 IiZl 012/025

Modified Enter the text here that is the new public health relevance information for your application. Using Using no more than two or three sentences, describe the relevance of this research to public health. relevance of this research to public health. no than Public Health Relevance Modified Public Health Relevance The United States of America is at risk of terrorist attacks using poxviruses or using pathogenic fungi. Both are also current medical problems. We propose to fungi. Both are medical problems. develop improved small molecule therapy targeting the Holliday junction resolving enzymes encoded by these pathogens as new treatments for infection. resolving Z-0 13 s-0� Have 06/19/2009 11 :20AM (GMT-O'4:OO) 11:20AM (GMT-04:00) 06/19/2009 10:32 FAX 06/19/2009 215 9557 215 898 9557 UPENN !IICROBIOLOGY MICROBIOLOGY L l!IJ 015/025 Program OlrectorlPrlnclpallnvestigator:J:!ushman, Frederic Dixon Frederic Dixon Program Director/Principal investigator:ushman, FREDERIC BUSHMAN, FREDERIC 10.08 cm ttl effort ACTIVE U19 AI078675 (Weiner, P1) U19A1078675 (Weiner, PI) 1/1/08-12131/13 1/1/08-12/31/13 0.96 calendar months NIH/IPCAVD NIH/ IPCAVD $152,853 Improving DNA Vaccines The goal of this project is to use pyrosequencing and DNA bar coding to study immune pressure, in project s coding order to guide the design of improved DNA vaccines. vaccines. R01 A1052845 (Bushman, P1) ROl AI052845 (Bushman, PI) 4/1/08-3/31/13 2.4 calendar months NIH $225,000 Favored Sites for HIV cDNA Integration in the Human Genome is to improve our understanding of HIV DNA integration mechanisms. The goal of this project s to improve our understanding of HIV DNA integration mechanisms. MARCE RFP (Bushman, P1) (Bushman, PI) 3/1/09-2128/14 3/1109-2/28/14 MARCE $175,000 Inhibition of DNA Modifying Enzymes of Category A-C Agents Inhibition Agents The goal of this project is to develop therapeutics against Category A-C Agents Cam ... .'.. P') 0 o�' RFAAI08018 (June, P1) 3/1109-2128/14 RFAAIO8OI8 (June, PI) 3/1/09-2/28/14 0.96 calendar months NIH $173,248 Combination immunotherapy with gene modified CD4 and CD8 cells and stem cells modified The goal of this project is to use deep sequencing to analyze samples from cell therapy trials to treat HIV. O'^> 'co a0. ::2 coy E en, P') 0.96 calendar months ado i`4 R01 A1082020 (Bushman, P1) 6/15/09-5/31/13 2.4 calendar months ROl AI082020 (Bushman, PI) NIH $250,000 Massively Parallel Analysis of Integration in Therapeutic Gene Transfer SCID-X1 The goal of this project is to use deep sequencing to analyze integration in SCID-X1 gene therapy. fl= o`' E E PENDING' Effort will be adjusted on pending grants if funded. PENDING * funded. LewiS, Co-Pis) 711109-6/30/13 UH2HGOO4994 UH2HG004994 (Wu, Bushman, Lewis, Co-PIs) 7/1/09-6/30/13 NIH $700,000 Diet, Genetic Factors, and the Gut Microbiome in Crohn's Disease The goal of this project is to analyze the role of gut flora in Crohn's disease (/f 61.y _�oo U01 Al (Bushman PI) 611/09-5/31/14 2.4 calendar months U01 AI 082015 (Bushman P1) 6/1/09-5/31/14 this grant NIH/NIAID Broad Therapeutics Targeting Resolvase Enzymes Broad Spectrum Therapeutics Targeting Resolvase Enzymes The goal of this project its to carry out basic and pharmacological studies of resolvases. 0x� RFA HL-09-006 (Coliman and Bushman Co-PIs) (Collman Co-Pis) 9/30/09-8/29/14 calendar months 2.4 calendar months NIH/NHLBI $525,000 Human Respiratory Tract Microbiome in Health, HIV Infection and HIV Lung Disease of project is use sequencing respiratory microbiome The goal of this project is to use high density deep sequencing to examine the respiratory microbiome in HIV infected and uninfected individuals with COPD. individuals with COPD. -'I =-O PA-06-181 (Bushman, P1) (Bushman, PI) 12/1/09-11130/11 1.2 calendar months 12/1/09-11/30/11 NIH $125,000 Deep-sequencing for HIV genotyping in resource-limited settings resource-limited of project is method use in resourceThe goal of this project is to develop a method for genotypic drug resistance testing for use in resourcelimited settings. 3 �2_ 3�� OVERLAP: None. 0 (DO ..0 PHS 39812590 (Rev. 11/07) 398/2590 '20 o6� p�QU 1.8 calendar months 1.8 464 cr.. 0'o 0.2 22_ a)>_ >.S2 O-- Page_ Page 14 other Support Fonnat Page Other Support 06/19/2009 11:20AM (GMT-04:00) 11 :20AM (GMT-014:00) 06/19/2009 10:32 FAX 06/19/2009 215 898 9557 215 9557 UPENN MICROBIOLOGY E IiZl 016/025 Program Direetor/l'rincipallnvestlgator: Bushman. Frederic Dixon Program Director/Principal Investigator: Bushman, Frederic Dixon ISAACS, S.N. ACTIVE 6.6 cm 3.60 calendar U01 AI066333 (lsaacs, P1) 7/5/2005 - 6/30/2010 U01 A1066333 (Isaacs, PI) NIH/NIAID $225,000 Smallpox vaccine and vaccinia complement control protein Th is project examines the deletion of the gene encoding the vaccinia virus complement control protein as a of protein as a This more strategy to generate a safer, but more efficacious smallpox vaccine. U01 A1077913 (Isaacs, P1) 5/1/2008 - 4/30/2013 5/1/2008-4/30/2013 U01 A1077913(lsaacs, PI) ~$425,000 -$425,000 NIH/NIAID NI H/N lAl D Optimizing the formulation of a protein based smallpox vaccine �0O The goal of this project is to develop a safe and effective protein-based smallpox vaccine using variola proteins. .O. 0<0 0020 1.2 calendar E This project will investigate viral and cellular proteins involved in poxvirus entry into cells. PENDING None OYERLAP OVERLAP None m z %20 PHS 398/2590 (Rev. 11/07) 11107) PHS em. U54 AI057168 (Levine, overall PI for MARCE) 3/1/2009 - 2/28/2014 1.8 calendar U54 A1057168 (Levine, overall P1 for MARCE) NIH/NIAID $235,000 Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Program 2: Emerging Virus Entry into Host Cells: Strategies for Inhibition Cells: 2: Inhibition Project 2.4: Mechanism of Poxvirus Entry into Cells (Gary Cohen. P1) of Entry into Cells (Gary Cohen, PI) 2.4: ACV page~ Page 15 Other Support Format Page Fonmat 06/19/2009 11 :20AM (GMT-0'4:00) 11:20AM (GMT-04:00) 06/19/2009 10:33 FAX 06/19/2009 215 9557 215 898 9557 UPENN MICROBIOLOGY IiZl 017/025 Program DirectorlPrincipallnvestigator: Program DiiactorlPrincipal Investigator: Bushman. Frederic Dixon Bushman, MADRID, PETER B. 4.2 cm ACTIVE DTRAlTMTI DTRA(TMTI Contract No.: HDTRA1-07-C-0083 No.: HDTRAI-07-C-0083 of Performance: 07118/07-07/17109 Period of Performance: 07118/07-07/17/09 Title: An Accelerated Path to Safe and Effective Therapeutics (APSET) for Bioterrorism Agents (APSEl) Title: Award Amount: $9,100,000 Time: 1.20 months Time: Mate. c13 NIHINIDDKD NII-I/NIDDKD (Subcontract to Numerate Inc.) Contract No.: 1R41DK081244-01A1 Contract No,: 1R41DK081244-O1A1 Period of Perfomance: 02101109 -- 01/31/2010 Period Perfomance; 02/01/09 0113112010 Title: Drug Engineering of Transglutaminase-2 Inhibitors of Award Amount: $54,000 Award Amount: Time: 3.00 months Time: PENDING NIH/NIAIO NIH/NIAID Period of Performance: 07/01/09 - 06/30/11 07101/09 06130111 Period of gyrase b histidine kinases broad-spectrum Title: Dual action inhibitors of gyrase b and histidine kinases as broad-spectrum antibiotics. Award Amount: $3,200,000 Time: 6.00 months OVERLAP None. "Q. s.N C0= o�A) t11 E PHS 398/2590 (Rev. 11/07) oar3E 01= coo �c. Page_ Page 2� Other Support Format Page Fonnat Page 06/19/2009 11 :20AM (GMT-0'4:00) 11:20AM (GMT-04:00) 06/19/2009 10:33 FAX 06/19/2009 215 898 9557 215 UPENN MICROBIOLOGY IiZl 018/025 t018/025 PrinClpallnvestlgatorlProgram Director: Bushman, Frederic D. Pflncipal Investigator/Program Director Bushman Frederic D. PHS 39812590 OTHER SUPPORT 398/2590 ORBACH, MJ 5.5 ttl cm ACTIVE 1 P01 Al061 31 0-01 Galgiani (P1) P01 A1061310-01 Galgiani (PI) 06/15/04 - 05/31/10 3.0 calendar NIHINIAID No cost extension NIH/NIAID Induction of Fungal Dormancy as a Potential Disease Therapy, Host Control in Coccidioldomycosis Therapy, Coccidioidomycosis The major goal of this project is to explore the genetic basis of quiescence in Coccidioides spp. using global CoccidiOides gene expression analysis and mutagenesis of differentially regulated genes. This grant is in a no-cost extension year. Role: Project Leader Role: OVERLAP: No overlap. -15 o'3 .N.' fan 0627159 Soderlund, C. (P1) Soderlund, C. (PI) 12/01/06 -11/30/09 1.0 calendar 12/01/06 - 11/30/09 Foundation No cost extension National Science Foundation Community Database for studying rice-rice blast interactions. a platform This will The goal of this project is to set up a community annotation platform for the Magnaporthe genome. This will include addition of mutant information generated by a previous NSF project along with encouraging addition participation by the research community. This grant is in a no-cost extension year. community. This grant is in a no-cost extension year. Role: Role: Co-PI OVELAP: No overlap. -15yct (�d MJ (PI) 58-6435-8-315 Orbach, MJ (P1) 8/1/08-07/31/13 0.5 calendar USDA Cooperative Agreement $28,622 Influence of Agrichemicals on Aspergillus Communities and Aflatoxin Management. Aflatoxin Management. The goals of this project are to determine whether the application of agrichemicals aimed at weed control affects reSistance of fungi in the fields to those chemicals. If so, resistant strains of Aspergillus species used as resistance chemicals. so, reSistant biocontrol agents will be selected for and tested for efficacy as biocontrol agents compared to non-resistant biocontrol strains. OVERLAP: No overlap. =ENO 3 PENDING U01 Al08201 5-01 (Orbach - subcontract) UO1 A1082015-01 1.0 calendar NIH this grant $73,554 Broad Spectrum Therapeutics Targeting Resolvase Enzymes Broad Coccidioides on The goal of this research is to determine the effect of eliminating the resolvase gene from Coeckiloides on for virulence of the fungus for mammalian hosts and to develop small molecules targeting this gene for therapy. for the current proposal. OVERLAP: This is for the current proposal. .-. o 17 06/19/2009 11:20AM (GMT-04:00) 11 :20AM (GMT-0L:00) -10 .2'y E"w 460 035 o4) ���f7�mW C ELL 4�"5 +-' ID.. 06/19/2009 10:33 FAX 06/19/2009 215 9557 215 898 9557 UPENN MICROBIOLOGY IiZl 019/025 Program Di_orlP,incipallnvestigator: Director/Principal Invesugator: Bushman. Frederic Dixon Bushman, Frederic Dixon SHUBITZ. LISA F. F. SHUBITZ, ACTIVE 11.6cm AI06131 0-030001 (Galgiani) 06/15/04 -05/31/09 0.5 calendar 1 P01 A1061 310-030001 (Galgiani) 06/15/04 -05/31/09 no cost extension NIH/NIAID Histological Marker of Resistance to Coccidioidomycosis, Host Control in Coccidioidomycosis The develop histopathological responses infection in the The major goals of this project are to develop histopathological profiles of host responses to infection in the lungs of genetically resistant mice and compare this profile to the responses of genetically susceptible mice, responses of genetically susceptible mice, and to identify vaccine formulations and protocols that result in histologic patterns closest to those found formulations in histologic patterns those found and with resistance. 150 7Z' 00- 1 P01 A1061 310-030004 (Galgiani) P01 AI06131 0-030004 0.5 calendar 06/15/04 -. 05/31/09 NIH/NIAID no cost extension BSL3 Animal Laboratory, Host Control in Coccidioidomycosis The major goals of this project are to provide a murine model of coccidioidomycosis to study the hostpathogen interactions in the respiratory tract in order to understand the early immunological events that lead pathogen to either resolution of infection or progression with development of clinical disease. of infection or progression with development of 0 6-0 .m. 1.0 calendar (Galgiani) 01/01/00- 12131109 01/01/00 - 12/31/09 California Health Care Foundation $198,052 California Health Care Foundation $198,052 Project, Phase II Valley Fever Vaccine Project, Phase II is identify antigens may be The goal of this project is to identify antigens that may be useful in a practical vaccine to prevent coccidioidomycosis in humans. (p' 03/01/09 - 2/28/11 3.0 calendar 2128/11 1 R42A1074157�01A1 (Galgiani) R42A10741 57-01 Al (Galgiani) NIH/NIAID $303,525 Experimental Pharmacology and Chemical Studies of Nikkomycin Z - Phase II Phase II is perform pharmacological and new therapy for The goal of this project is to perform pharmacological and chemical studies on a promising new therapy for Fever. Valley Fever, U54A1065359 (Galgiani) 5/1/09-4/30/10 6.0 calendar US4AI 065359 Pacific Southwest Regional Center for Excellence $189.000 Pacific $189,000 Coccidioides Proteins as Vaccine Antigens and Diagnostic Biosignatures more Fever The major goals of this research are to create a more sensitive diagnostic test to distinguish Valley Fever from course of disease, and identify vaccine antigens that will early in other causes of pneumonia eatly in the course of disease, and to identify additional vaccine antigens that will for FDA approval. be easier to formulate for FDA approval. CO/ m.. OVERLAP: OVERLAP: None PENDING U01 A1082015-01 (Orbach 0.6 calendar UO1 Al08201 5-01 (Orbach - subcontract) NIH this grant $73,554 (Initial funding period) Broad Spectrum Therapeutics Targeting Resolvase Enzymes .Coccidioides on The goal of this research is to determine the effect of eliminating the resolvase gene from Cciccidioides on virulence of the fungus for mammalian hosts and to develop small molecules targeting this gene for therapy. s-. ('p 5." -"3 -(9 PHS 398/2590 (Rev. 11/07) 11107) PHS 8 page-2.. Page Other Support Format Page support Fonnat Page 06/19/2009 11 :20AM (GMT-014:OO) 11:20AM (GMT-04:00) ffi WO.O mom= O_' >+_ v=a arc _a0 dry 044 E moc pea U`0 fir} am' 06/19/2009 10:34 FAX 06/19/2009 215 898 9557 215 9557 UPENN !IICROBIOLOGY MICROBIOLOGY L l!IJ 020/025 IACUC Verification IACUC Verification use and IACUC approval: Animal use and IACUC apDroval: see revised IACUC protocol We have an IACUC approval protocol number 708172, "Therapeutic Interventions After Vaccinia Virus Infection", approval date 8/812006, that we are Infection", 8/8/2006, now connecting administratively to this proposal. Animal work will not start this proposal. immediately, allowing time for administrative adjustment. . 14 Cu. ft.; 115V 60Hz Models> 14 cu. ft.; IISV 60Hz Freezers, Fisher Scientific Isotemp Basic Chest; -86 0 to -40�C; 14.0 cu. ft.; Meet Freezers, Fisher Scientific Isotemp Basic chest; -86� to 40�C; 14.0 cu. ft.; Meet UL and CUL criteria; 115V 60Hz UL and CUL criteria; 11W 60Hz 1. ! Submitl Substructure Search i , ! ~ Certi~cate Of Analysis _~! ____________-- S' I Shopping Cart Shopping Cml No No items in cart View Cart cart For security reasons you will For secuilty you will be automatically logged out of inactivity. after 30 minutes of inactivity, a Item Description Catalog Number 13- 990- 32 13 990, 32 5'' Quantity , Price Each for $8,132.74 Each for $8132.74 14 cu. ft.: 115V60Hz l4cuft.: 11$V6OHz rrademorks I 'rerms dod Conditions ! Legal Notices I Privacy Policy I Thermo Fisher Scientific Inc. Trademarks Inc. terms and Conditions I Legal Privecy I ii nnrnL_ C/17/flflnn https://www.fishersci.com/wps/myportal/ITEMDETAIL?ru=hr 06/1 9/26 6911 c :'"'2'O-AM (GMT-0L:00) https;llwww.fishersci.com/wps/myportaiIITEMDETAIL?ru=ht. 0'6/1 9/2009 11:20AM (GMT~O"4: 0 0) 03= 2009 Thermo Fisher Scientific Inc. ~ All rights reserved. 2009 Thermo Fisher Scientific Inc. - All rights reserved, 20 06/19/2009 10: 34 FAX 06/19/2009 10:34 FAX 215 898 9557 215 898 9557 UPENN !IICROBIOLOGY UPENN MICROBIOLOGY I4l 022/025 1dj022/025 Fisher Scientific - Fisher Scientific* Isotemp* Basic UltraJow-Temperature Freezers: Che... Page 1 of 3 Scientific - Fisher Scientific* Isotemp* Basic Ultraiow-Temperature Freezers: Che,.. 1 of MALI 13509166 SKOTHEIM MALI 13509166SKOTHEIM Fisher PunchOu! Partner Fisher PunchOut Place Rapid Order - V1 Place Rapid Order VI. - My Hotllsts Hotlists - VI. Vk - My Templates - Re Re - My Quotes MSDS Home Home i Browse by: Product - Supplier - Application Application: by: Help I 113-990-32 13-990-32 I � Q=[ Search '-'I . �.i I I .. Back to Search Results Back to Search ~!llFisher Sclentific* lsotemp* Basic Ultralow-Temperature Freezers: ( flh Fisher SCientific*lsotemp' Basic Ultralow-Temperature Freezers: E 5ubji Substructure Search I ,submit]lCerflficateOfAnas Search L_' _9f Substructure Certlficate An~~~ I I for a variety of Industrial-process and general st Ideal for a variety of Industrial-process and general st Secure anatomy components, DNA, blolog Secure storage for anatomy components, DNA, biolog design for easy access contents. profile design for easy access to contents 4-' Custom i L",~,",_~~~~~,,~ ,~ Shopping Cart Vtew cart View Cart No items in cart No For security reasons you will be automatically logged out be automatically logged out after 30 minutes of inactivity. 13-990-19 Items E Details Images Description � Temperature range from -86� to -40�C Temperature range from -40�C Capacities from 3 to 14 cu, ft. 396L) � Capacities from 3 to 14 cu. ft. (85 to 396L) Manual � Manual defrost and Solid-state Control and Alarm Systems � � � � � � Adjustable digital display Adjustable temperature setpolnt with push-button digital display setpoint Key-operated main power switch Key-operated main overtemperature safety alarm with battery backup Integrated overtemperature safety alarm with battery backup Temperature deviation or prolonged power failure triggers audible alarm Temperature deviation prolonged Exterior alarm contacts for connection to remote monitoring system connection monitoring system boost compensates low voltage and brownout condi Automatic voltage boost compensates for low voltage and brownout cond Air-cooled Refrigeration System† � � � � � Two flip Copeland* compressors lhp Copeland* compressors CFC-free DuPont* Suva* 95 CFC-free DuPont* Suva* 95 low-stage refrigerants Downfeed evaporator provides highly efficient refrigerant flow Downfeed evaporator provides highly efficient High-capacity air-cooled condenser with dual condenser fans condenser condenser fans High-capacity Washable condenser (no tools required for removal) keeps fins free� washable condenser filter (no tools required for removal) keeps fins free rd'' Construction a Heavy-gauge steel exterior with high-impact powder paint finish � Heavy-gauge steel exterior with high-impact powder paint finish Heavy-gauge steel interior � Heavy-gauge steel Interior with rounded corners for easy cleaning rounded corners for easy cleaning In. thick (12.7cm) foamed-In-place, closed-cell, CFC-free uretl � Minimum 5 in. thick (12.7cm) foamed-in-place, closed-cell, CFC-free ureti ambient conditions � 1 In. dla. (2.5cm) access port with cap on back access cap on back in. dia. � Heavy-duty counterbalanced lid has built-in keyed lid lock for security counterbalanced lid has built-In keyed � Double-seal lid gaskets and Styrofoam* subllds minimize frost buildup Double-seal lid gaskets and Styrofoam* subllds � Recessed, heavy-dutL~.wlvel casters 11\1~~1'1 two levelll12.J~s -.__Recessed,_heavy-duty swivel_cas ''' . Specifications & Ordering Information: Stainless-steel interior, acces~~~~'::!p~!1d equipment_~!llidation servi~~!yailable: contact y_?ur your Sta!.,!~~!!-stee~!~~~erior, accessories and equipment validation service available; T ,/1 1/Info https://www.fishersci.comlwps/myportal/!utlp/cl/O45B8K8f 06i"19/20Tl09-- Tl 1'1":2CfAM (GMT-0L:00) https:llwww.fishersci.com/wps/myportaJ/!ut/p/cl104_SB8K8x 06/1 9/2009 11:20AM (G~T~"8~~ 00) pje!!j!91J!_ - .or --o 21 21 .,n ,rn,onnrnn.. 06/19/2009 10:35 FAX 10: 35 FAX l4023/025 UPENN MICROBIOLOGY 215 898 9557 UPENN !IICROBIOLOGY I4l 023/025 215 898 9557 Scientific Fisher Scientific* Isotemp* Ultralow-Temperatnre Freezers: Chc... of Fisher Scientific -- Fisher Scientific* Tsotemp* Basic Ultralow-Temperature Freezers: Che... Page 2 of 3 Certifications: Individually calibrated against equipment with calibration certified traceable Certifications: Individually calibrated against equipment with calibration certified traceable tt, . Warranty: Two years, parts and labor (extended 12-month warranty available; must be purc Warranty: Two years. parts and labor (extended 12-monlh warranty available must be pure -------.----~----.--- 4-F agreement Service agreement available. , I Interior D x W x x I Interior D x Capacity Exterior L x W x ! Hi Ht H* Shipping Weight W&ght .O. , Electrical 611 Requirements 115V 60Hz 115VEOHz 3 cii. ft. cu. ft. (85L) 17 x 19 x 17 in. (43 30 x 30*451. (76 lb 17 30 x 30 x 45 in. (78 415 lb.. . x48 *43cm) x 43cm) . (188kg) : x76x116cm) *76*116cm) t"1 ++: � 2081240V 60Hz 208/24QV60Hz 220V50Hz 220 V 50Hz 115V 60Hz 115V6OHz 7 cu. It. 7cu. ft. (198l) (1981) . 19x23112x26112 30x48112x41 in, 19 *231/2 *261/2 30 *481/2 *41 in. in. (48 x 60 )( 67cm) (76*123*104cm) fl. (48*60 x 67cm) (76 x 123 x 104cm) 525 lb. (238kg) ____________ 2081240V 60Hz 208/240V 115V60Hz 115V 60 Hz 10cu.ft. 10 Cu. ft. (283l) (283L) �19x35114x26112 i 30x60112x41 in. ! 680 lb. 680 lb. 19 x 351/4*261/2 30 x 601/2 x 41 in. (46*90*67cm) (76 x 154 x 104em) in,(48 x 90 x 67cm) ! (76*154*104cm) � (308kg) 2081240V 60Hz 206/240V60H 2 220V50Hz 115V 60Hz 115V6OHz 14 cu. ft. 14 cu. (396l) (396L) 19 x 47xx261/2 in, 19*47 26112 in. (48 x 119 x 67cm) (48 x 119*67cm) � 30 x 72 x 41 in. (76 30 x 72 *41 in. (76 x183x104em) x 183* 104cm) 680 lb. (308kg) 2081240V 60Hz 208/240V 220V50Hz ... 22 https://www.fishersci.com/wps/myportal/!ut/p/c 1 iC/i 1/flflflfl /04_SB8K8xLT 1t40?tifQ r7uuQ,,nwornnnr 06/19/2009 11:20AM (GMT'-014:00) \_y 06/19/2009 10:35 FAX 10:35 FAX 215 898 9557 215 898 9557 UPENN MICROBIOLOGY UPENN MICROBIOLOGY Cps 14j024/025 I4l 0241025 {!Q Fisher Scientific - Fisher Scientific5 Isotemp* Basic Ultralow-Temperature Freezers: Che... Page 3 of 3 Scientific� Che... 0[3 †Cascade system includes first-stage (blend of R-134a and R4O4a) and seconiFsta' R~404a) and second-sta, †Cascade system Includes first-stage (blend of R134a ‡:PubJished interior volumes are nominal; usable capacities may be offset by shelves, dr ‡Published interior volumes are nominal; usable capacities may be offset by shelves, dr dimensions and allowances, or for verification of clearance tolerances, contact your Fisher Sci tolerances, Sd "I Back to Search Results 4 Back to Tradernarks Trademarks I Terms and Conditions COnditions I Legal I L..eg,,1 Notices I Privacy Policy I Thermo Fisher Scientific: Inc. Policy Scientific I 2009 Thermo Fisher Scientific Inc. All rights reserved, 2009 Thermo Fisher Scientific Inc. - All rights reserved. '-L 23 06/1 9/2009 ry https://www.fishersci.comiwps/myportal/!utfp/cl/04sBSK8XT t arnw =ti All 7/')IIflQ 06/19/2009 10:35 FAX 10:35 FAX 215 898 9557 215 898 9557 UPENN !IICROBIOLOGY UPENN MICROBIOLOGY t025/025 l!IJ 025/025 Program Director/Principal Investigator (Last First, Middle); DireclorlPrincipallnvestigator (Last. First, Middle): Bushman, Frederic CHECKLIST TYPE OF APPLICATION (Check all that apply,) 1YPE that apply) o o o o o o C8l NEW application. (This application is being submitted to the P1-ISfor the fiBt time.) application, (This applicanon i. being submittlJd to the PHS tot the first tine.) RESUBMISSION of application number: (ThIs applicaoon replaces a prior unfunded versIon of a new, renewal, or revision application.) 8 prior unfunded version of or (This application `O_ RENEWAL of grant number. El RENEWAL of grant number (ThIs application is to a.f.8OO a funded grant beyond ifs current project period.) (This application is to extend a fluidS grant beyond its period.) REVISION to grant number: number: (ThIs applica/jon is lor edditional funds to supplement a currently funded grant.) (This application for additional funds supplement a current(y funded grent) "�N CHANGE program directorlprincipal investigator. [I] CHANGE ofof program directorlprincipalinvestigator. Name of former program director/principal investigator: direclor/principal CHANGE of Grantee Institution, Instttution. Name of former institution: instttution: Ust Ctsy(ies) Countly(ies) Involved: Z FOReiGN application Domestic Grant wkh foreign involvement [II FOREIGN application 0 Domestic Grant with foreign involvement INVeNTIONS AND PATENTS (Renew./appl. only) INVENTIONS AND PATENTS (Renewal appl. only) .St 0 1. PROGRAM INCOME (SH InSlt'uetlons.) PROGRAM INCOME (See instructIons.) All applications must Indicate whether program income is anticipated during the period(s) for which grant support is request. If program income is indicate Income Is anticipated during the panod(s) tor grant support Is requesl. income Is anticipated. use the format below to reflect the amount and source(s). tormat below to reflect the amount and source(s). anticipated, Budaet Period Anticipated Amount SourceCs) E DNo 0 No DYes 0 Ves If"Yes,' 0 Previously reported 0 Not previously reported Previously reported Not previously reported If Yes,' D D N/A $0.00 N/A 2. ASSURANCESICERTIFICAnONS (See Instructions,) 2. ASSURANCE$!CERTIFICATIONS (SH Instruclions.) In signing the application Face Page, the authorized organizational representative agrees to comply with the policies, assurances and/or certifications Page, authorized organizational representative agrees to comply with the policies, assurances andlor cartifications listed in the application instructions when applicable. Descriptions of individual assurances/certifications are provided in Part Ill and listed in Part 1,4.1 applicable. Descnplions of individual assurances/certifICations are provided in Part III and listed in Part I, 4.1 under Item 14. If unable to certify compliance, where applicable, provide an explanation and place it after this page. compliance. applicable. provide an explanation and place tt alter this page. 3. FACILITIES AND ADMINSTRATIVE COSTS (F&AJl INDIRECT COSTS. See specific instructions. FACILITIes AND ADMINSTRATIVE COSTS (F&AV INOIRECT COSTS. See specific instructions. sumo o o DHHS Agreement dated: 05/15/09 C8l DHHS Agreement dated: ~~~-----------------05/15/09 DHHS Agreement being negotiatedwith DHI-IS Agreement being negotiated'w~h No DHHS Agreement, but rate established with rate established wilh CALCULATION' (The enke grant application, including the Checklis4 will be reproduced and provided to PH' reviewers as confidential inlormaoon.) fo peer reviewers as confidential information,) CALCULATION (Tha entire grant appllceoon, including the Check6s~ will be reproduced and a. lnltialbudgetperiod: a. Inttial budget period: b. 02 year b. 02 Amount of bese $ Amountofbase Amount of base $ Amount base Amount of bese $ Amount of base Amount of base $ Amount of base S Amount of base $ base $ W=a - did not include 0 No Facilities $25,000 exclusionRequested. LI] NO Facilttlas And AdministrativeCosts Requested. And Administrative Costs Date _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Regional Office. RegionaI01llce. 434,429 384,429 x Rate applied 384,429 * Rate applied 57.5/59 %=F&Acosts 57.5/59 % =F&A costs 59/60 % =F&A costs = FM costs $ $ $ $ $ $ $ $ $ $ $ 255,778 230,337 CID c. 03 year c. 03 d. 04 year d. 04 e. 05year e. 05 year _ _ _ _ _ _ ~ Rate applied _ _ _ _ _ % = F&A costs _______________x Rate applied %=F&Acosts _ _ _ _ _ _ x Rateapplied _ _ _ _ _ % =F&A costs %tF&Acosts ____________x Rate applied ________________ _ _ _ _ _ _ x Rate applied _ _ _ _ _ % � F&A costs x Rate applied %FMcosts TOTAL F&A Costs TOTALFMC0sta __________ __________ 486,115 486,1151 o o �Check appropriate box(es) theck appropriate box(es): Salary and wages base LII Salary and wages base C8l Modified total direct cost base o Other base (Explain) base Off-stte, Off-site, other special rate, or more than One rate involved (Explain) one involved (explain) Explanation (Attach separate shaet, if necessary.): Explanation (Attach saparaf.8 sheet, necessaayj: 06/30/09=57.5% Thru 06/30109=57.5% 07/0112009-06/30/10=59% 07/01/2009-06/30/10=59% After 07/01/2010=60% DISCLOSURE PERMISSION STATEMENT: this application does not result In an award, is the Government permitted to disclose the title of 4. DISCLOSURE PERMISSION STATEMENT: If If this application does not resultin an award, is the Government permitted to disclose the title of project, the name, address, telephone number and e-mail address of the offICi_I signing for the applicant 0 anizatlOn, your proposed profect, and the name, address, telephone number and e-mail address of the official signing for the applicant orq,anization, to ..2 troll o anizatlons that ma be interested in contactin PHS 398 (Rev. 11107) PHS 398 (Rev. 11/07) -�' (Do ou for further information (e. "possible collaborations, investmen!)? Page ___ Page ' Ves No Checklist Form Checklist Form Page 06/19/2009 11 :20AM (GMT-0L:00) 11:20AM (GMT-04:00)